Moderna reports first positive Phase 3 for mRNA neoantigen therapy in melanoma

Today marks an important milestone for

, for the section of mRNA, and for the galore group moving to bring caller possibilities to patients. This morning, Moderna and Merck announced affirmative Phase 3 results for adjuvant curen pinch intismeran autogene, an individualized mRNA therapy for melanoma, successful operation pinch KEYTRUDA, successful patients pinch wholly resected shape IIB-IV melanoma. The study met its superior endpoint of recurrence-free endurance and a cardinal secondary endpoint of distant metastasis-free survival. This is the first affirmative Phase 3 consequence for an individualized neoantigen therapy, and the first for an mRNA-based crab therapy. When we founded Moderna successful 2010, the thought that mRNA could go a caller people of medicines was outright rejected. The thought that we mightiness usage it to create a therapy designed astir the unsocial mutations successful an individual patient’s tumor was moreover further from reality. Today’s consequence is simply a reminder of what tin look from pioneering: asking questions others person not yet asked, pursuing the subject wherever it leads, and persevering done uncertainty. There is important activity still up but coming is simply a infinitesimal to admit the bonzer activity down this milestone. Congratulations to the full Moderna team, our partners astatine Merck, and the investigators who made this study possible. Most importantly, my gratitude goes to the patients and families whose information enables advancement for illustration this. Proud of this milestone, and of everyone who helped bring america here.